Your browser doesn't support javascript.
loading
FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma.
Tao, Zhanchao; Cui, Yue; Xu, Xilong; Han, Ting.
Affiliation
  • Tao Z; Graduate School of Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China 100730.
  • Cui Y; National Institute of Biological Sciences, Beijing, China 102206.
  • Xu X; National Institute of Biological Sciences, Beijing, China 102206.
  • Han T; Graduate Program, School of Life Sciences, Beijing Normal University, Beijing, China 100875.
Proc Natl Acad Sci U S A ; 119(40): e2208844119, 2022 10 04.
Article in En | MEDLINE | ID: mdl-36179047
ABSTRACT
Aberrant fibroblast growth factor 19 (FGF19) signaling mediated by its receptor, FGF receptor 4 (FGFR4), and coreceptor, klotho ß (KLB), is a driver of hepatocellular carcinoma (HCC). Several potent FGFR4-selective inhibitors have been developed but have exhibited limited efficacy in HCC clinical trials. Here, by using HCC cell line models from the Cancer Cell Line Encyclopedia (CCLE) and the Liver Cancer Model Repository (LIMORE), we show that selective FGFR4 inactivation was not sufficient to inhibit cancer cell proliferation and tumor growth in FGF19-positive HCC. Moreover, genetic inactivation of KLB in these HCC cells resulted in a fitness defect more severe than that resulting from inactivation of FGFR4. By a combination of biochemical and genetic approaches, we found that KLB associated with FGFR3 and FGFR4 to mediate the prosurvival functions of FGF19. KLB mutants defective in interacting with FGFR3 or FGFR4 could not support the growth or survival of HCC cells. Genome-wide CRISPR loss-of-function screening revealed that FGFR3 restricted the activity of FGFR4-selective inhibitors in inducing cell death; the pan-FGFR inhibitor erdafitinib displayed superior potency than FGFR4-selective inhibitors in suppressing the growth and survival of FGF19-positive HCC cells. Among FGF19-positive HCC cases from The Cancer Genome Atlas (TCGA), FGFR3 is prevalently coexpressed with FGFR4 and KLB, suggesting that FGFR redundancy may be a common mechanism underlying the de novo resistance to FGFR4 inhibitors. Our study provides a rationale for clinical testing of pan-FGFR inhibitors as a treatment strategy for FGF19-positive HCC.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Journal: Proc Natl Acad Sci U S A Year: 2022 Type: Article